Evidence map›Paper›PMID 32901685›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2020

Anti-inflammatory and antinociceptive effects of the isatin derivative (Z)-2-(5-chloro-2-oxoindolin-3-ylidene)-N-phenyl-hydrazinecarbothioamide in mice.

L L S F R Dantas, A G Fonseca, J R Pereira, A A Furtado, P A T M Gomes, M F Fernandes-Pedrosa, A C L Leite, M J B M Rêgo, M G R Pitta, T M A M Lemos

Open access · goldAbstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Synthesis, characterization, andFrontiers in pharmacology · 2025
    Article
  3. Discovery of New 3-(Benzo[Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  4. Article
  5. Article
  6. Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

L L S F R DantasPrograma de Pós-Graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos, Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil.ORCID http://orcid.org/0000-0002-6739-8776
A G FonsecaPrograma de Pós-Graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos, Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil.ORCID http://orcid.org/0000-0002-6366-9081
J R PereiraPrograma de Pós-Graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos, Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil.ORCID http://orcid.org/0000-0002-0748-0268
A A FurtadoPrograma de Pós-Graduação em Bioquímica, Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil.ORCID http://orcid.org/0000-0002-9623-0032
P A T M GomesPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Pernambuco, Recife, PE, Brasil.ORCID http://orcid.org/0000-0001-7089-5653
M F Fernandes-PedrosaPrograma de Pós-Graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos, Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil.ORCID http://orcid.org/0000-0003-4221-9580
A C L LeitePrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Pernambuco, Recife, PE, Brasil.ORCID http://orcid.org/0000-0002-9346-2292
M J B M RêgoNúcleo de Pesquisa em Inovação Terapêutica Suely Galdino, Universidade Federal de Pernambuco, Recife, PE, Brasil.ORCID http://orcid.org/0000-0002-1883-6012
M G R PittaNúcleo de Pesquisa em Inovação Terapêutica Suely Galdino, Universidade Federal de Pernambuco, Recife, PE, Brasil.ORCID http://orcid.org/0000-0001-5881-0338
T M A M LemosPrograma de Pós-Graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos, Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil.ORCID http://orcid.org/0000-0001-7118-2145
Universidade Federal do Rio Grande do Norte · BRUniversidade Federal de Pernambuco · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several isatin derivatives have shown important biological activities, which have attracted interest from researchers. For this reason, the present study aimed to evaluate the anti-inflammatory and antinociceptive effects of the isatin derivative (Z)-2-(5-chloro-2-oxoindolin-3-ylidene)-N-phenyl-hydrazinecarbothioamide (COPHCT) in mice. Three doses of this compound were tested: 1.0, 2.5, and 5.0 mg/kg. The anti-inflammatory activity was assessed using the carrageenan-induced paw edema model and the zymosan-induced air pouch model. The evaluation of the antinociceptive effect was performed through the formalin test and the acetic acid-induced abdominal writhing test. The paw edema assay demonstrated that all doses of the compound showed a significant reduction of the edema in the second hour evaluated, but a better response was observed in the fourth hour. The zymosan-induced air pouch model indicated that the compound, in all doses, significantly reduced leukocyte migration and total protein concentration levels. In the formalin test, the doses 1.0, 2.5, and 5.0 mg/kg of COPHCT showed activity only in the second phase, with reduction in paw pain time of 73.61, 79.46, and 73.85%, respectively. The number of abdominal writhings decreased with the increasing dose, but only 5.0 mg/kg COPHCT exhibited a significant response, with a reduction of 24.88%. These results demonstrated the ability of this compound to interfere in the anti-inflammatory activity of edema, vascular permeability, and cell migration. In addition, its possible antinociceptive effect may be related to the dose used.

Indexed as

AnalgesicsAnimalsAnti-Inflammatory AgentsCarrageenanEdemaFemaleIsatinMaleMicePlant ExtractsAnalgesicsAnti-Inflammatory AgentsCarrageenanIsatinPlant Extracts

Identifiers

PMID32901685
PMCPMC7485313
OpenAlexW3084123658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.